Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103350 · ClinicalTrials.gov registry record · Phase 1
Safety of TG100-115 for Heart Attack Treated With Angioplasty
A Phase 1 study, sponsored by TargeGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00103350 is a Phase 1 study that has completed, run by TargeGen. The registered enrollment target is 100 participants.
The verdict
NCT00103350, a Phase 1 study, has completed, sponsored by TargeGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces heart muscle damage.
Interventions
- DRUG TG100-115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103350
The ClinicalTrials.gov registry entry for NCT00103350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TargeGen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TG100-115 is the first listed.
NCT00103350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103350 about?
NCT00103350 is a clinical study titled "Safety of TG100-115 for Heart Attack Treated With Angioplasty". TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces heart muscle damage.
What is the current status of trial NCT00103350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00103350?
The interventions under investigation include: TG100-115 (DRUG).
Who is sponsoring clinical trial NCT00103350?
This trial is sponsored by TargeGen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.